Stem cell therapy for regenerating intervertebral discs - 16/07/2020 Ulm’s simulator has Europe’s back Back pain is often caused by intervertebral disc disorders. Much has already been tried and is available to help patients. Despite extensive progress, there is still no surefire recipe for success. iPSpine, an EU-funded project to which researchers from Ulm are contributing interdisciplinary engineering and biomedical expertise, aims to design a novel therapy for back pain based on intervertebral disc regeneration.https:////www.gesundheitsindustrie-bw.de/en/article/news/Ulms-simulator-has-europes-back
Article - 10/01/2019 Stocktaking and recommendations for action: the BBAW’s fourth gene technology report In the new gene technology report, the interdisciplinary working group of the Berlin-Brandenburg Academy of Sciences (BBAW) takes stock of gene technology developments in Germany during the past few decades, and discusses the societal, legal and ethical challenges associated with these technologies in the future. The report is highly topical due to the controversy surrounding the ruling of the European Court of Justice on CRISPR/Cas9 genome…https:////www.gesundheitsindustrie-bw.de/en/article/news/stocktaking-and-recommendations-for-action-the-bbaws-fourth-gene-technology-report
Press release - 24/01/2017 Cancer Medications Learn to Hide The European Research Council awards Wilfried Weber an ERC Proof of Concept Grant. Wilfried Weber, Professor of Synthetic Biology at the University of Freiburg, has received a grant of roughly €150,000 for his project “Hide and Seek with Cancer Drugs” in which he is working to improve the drugs used in cancer treatment.https:////www.gesundheitsindustrie-bw.de/en/article/press-release/cancer-medications-learn-to-hide
Article - 01/09/2016 Tailor-made biotech fibres for improved wound dressings Scientists have developed a biotechnological process to produce bacterial alginate. The alginate quality is highly reproducible, making it suitable for the production of fibre-based medicinal products such as wound dressings.https:////www.gesundheitsindustrie-bw.de/en/article/news/made-to-measure-biotech-fibres
Article - 29/08/2016 Cellendes and EU partners develop cell therapy for treating type 1 diabetes Cells derived from suitable donor stem cells that can do the work defective insulin-producing cells can no longer do are the central focus of a European cell therapy project involving Reutlingen-based Cellendes GmbH as one of the partners. Cellendes develops a biomaterial that facilitates the mass production of cells and could potentially be approved for therapeutic use in humans. https:////www.gesundheitsindustrie-bw.de/en/article/news/cellendes-und-eu-partner-entwickeln-zelltherapie-fuer-diabetes-typ-1
Article - 01/06/2015 High-tech fibres for organ and tissue regeneration Biologically degradable polymers can be electrically spun into a type of fleece that can be used as a scaffold and growth matrix for living cells. This fleece can be used to replace diseased or damaged tissue. In the field of cardiovascular medicine, the fleece can be used to produce new heart valves and tissue.https:////www.gesundheitsindustrie-bw.de/en/article/news/high-tech-fibres-for-organ-and-tissue-regeneration
The Baden-Württemberg healthcare industry Medical technology Medical technology is indispensible for human health and contributes a great deal to improving the quality of our lives. The field of medical technology covers many areas. These range from simple disposable products and consumables such as dressing materials and other clinical supplies, to IT-related telemedicine, homecare and eHealth systems as well as high-technology and innovative robotics, imaging, diagnostics and life-support systems. 851…https:////www.gesundheitsindustrie-bw.de:443/en/location/medtech
Article - 12/01/2015 Bionic chemistry: developing tailor-made functional units for bacterial cells Dr. Stefan Schiller from the Center for Biological Systems Analysis (ZBSA) at the University of Freiburg combines synthetic biology and synthetic chemistry concepts in order to equip bacterial cells with organelle-like compartments. He has countless biotechnological applications in mind. In 2014, Schiller received the research prize “Next Generation of Biotechnological Methods – Biotechnology 2020+”. The prize is awarded every two years and…https:////www.gesundheitsindustrie-bw.de/en/article/news/bionic-chemistry-developing-tailor-made-functional-units-for-bacterial-cells
Article - 01/09/2014 BARK CLOTH_europe – success through saving resources Ecological, economical and socially sustainable - all apply to a company called BARK CLOTH_europe, which in 2013 was one of 10 companies recognised as fabric innovators by the 'LAUNCH System Challenge: Fabric'. With its biomaterial made from the bark of the African Ficus tree, the company sells an innovative material that is produced using traditional methods.https:////www.gesundheitsindustrie-bw.de/en/article/news/bark-cloth-europe-success-through-saving-resources
Article - 05/05/2014 Michael Doser brings together biomedicine and textile research Textile products used for the treatment of wounds are increasingly being coupled with bioactive functions. A growing number of biocompatible and absorbable high-tech materials are used on and in the human body for therapy, diagnosis and measurements. Michael Doser, Director of Medical Engineering/Biomedical Process Engineering at the ITV Denkendorf, is working on innovative wound management products and processes.https:////www.gesundheitsindustrie-bw.de/en/article/news/michael-doser-brings-together-biomedicine-and-textile-research
Article - 07/04/2014 Christina Wege: from plant viruses to biomaterials Plant viruses can be engineered in many ways for use by and in humans. Amongst other things, they can be used as scaffold structures for bioactive molecules, which might help improve implants. Prof. Dr. Christina Wege from the University of Stuttgart is studying these and many more options for the use of harmless viruses for human application. https:////www.gesundheitsindustrie-bw.de/en/article/news/christina-wege-from-plant-viruses-to-biomaterials
Article - 24/02/2014 Enhanced feeling of well-being triggers regeneration New biomaterials are all the rage – especially in the Department of Oral Biotechnology, which was established at the Dental School and Hospital at the Freiburg University Medical Centre in 2008. The department’s laboratory manager, Prof. Dr. Thorsten Steinberg, takes an approach that is inspired by clinical application and aimed at developing biomaterials that support the wound healing process. This approach must, of necessity, include basic…https:////www.gesundheitsindustrie-bw.de/en/article/news/enhanced-feeling-of-well-being-triggers-regeneration
Article - 16/12/2013 Cellendes puts paradigm change in cell research to good use Cells grown on the flat furfaces of tissue culture plates do not behave as they would in their natural environment. This is why scientists are now using three-dimensional substrates to replicate the natural environmental of cells in tissue cellular matrix. Dr. Brigitte Angres and Dr. Helmut Wurst founders and managing directors of Cellendes GmbH in Reutlingen have taken advantage of this new knowledge and developed two novel hydrogels for cell…https:////www.gesundheitsindustrie-bw.de/en/article/news/cellendes-puts-paradigm-change-in-cell-research-to-good-use
Press release - 16/10/2013 BIOTECHNICA 2013 - Baden-Württemberg is a top life sciences spot. The BIOTECHNICA trade show rolled out the red carpet for its exhibitors. Over 10,000 visitors walked over the carpet to inspect the exhibits that were on display at the Baden-Württemberg booth. The impressive exhibits of the companies showed that Baden-Württemberg has many highly innovative SMEs in the life sciences field. https:////www.gesundheitsindustrie-bw.de/en/article/news/biotechnica-2013-baden-wuerttemberg-is-a-top-life-sciences-spot
Article - 24/06/2013 Cells and biomaterials for the treatment of intervertebral disc defects A new therapeutic method uses a patient’s own cartilage cells for the regeneration of intervertebral discs. The NMI Natural and Medical Sciences Institute in Reutlingen and its partners are scientific partners in the first clinical application of the new method. The key aim of the researchers from Reutlingen is the validation of the safety, efficiency and efficacy of the new method in order to prepare for approval for broad application in…https:////www.gesundheitsindustrie-bw.de/en/article/news/cells-and-biomaterials-for-the-treatment-of-intervertebral-disc-defects
Article - 08/04/2013 Integrated infrastructures for medical science The annual TMF conference in Heidelberg dealt with the need for integrated science infrastructures for the advancement of medical research. The major focus was on quality criteria for medical biomaterial banks and the establishment of the German Biobank Registry as the core of a central IT infrastructure, with the overall aim of creating the right conditions for resource-saving medical research excellence in Germany. https:////www.gesundheitsindustrie-bw.de/en/article/news/integrated-infrastructures-for-medical-science
Article - 31/12/2012 siRNA for the regeneration of tissue and nerves Regenerative medicine is increasingly making use of siRNA to turn off proteins that prevent the application of regenerative therapies. Researchers at the NMI in Reutlingen develop siRNA technologies that have the potential to prevent the development of fibroses, the encapsulation of implants and improve the regeneration of nerves. https:////www.gesundheitsindustrie-bw.de/en/article/news/sirna-for-the-regeneration-of-tissue-and-nerves
Article - 17/12/2012 Stefan Schiller – understanding and copying complex molecule systems Dr. Stefan Schiller from the Institute for Macromolecular Chemistry at the University of Freiburg became interested in the diversity of molecular possibilities in nature as a student and is now a specialist in bionic chemistry and synthetic nanobiotechnology. Amongst other things his work involves the construction of complex protein machines that transfer signals protein networks for use in medicine and drug shuttles that enable the targeted…https:////www.gesundheitsindustrie-bw.de/en/article/news/stefan-schiller-understanding-and-copying-complex-molecule-systems
Article - 10/09/2012 EU cooperations at the interface of research and industry It is also in the interest of small companies to look beyond their national borders: biotechnology and medical technology specialists in neighbouring European countries offer excellent prospects to German companies – and vice versa. Regional life sciences networks help establish and intensify contacts and collaborative activities between international partners.https:////www.gesundheitsindustrie-bw.de/en/article/news/eu-cooperations-at-the-interface-of-research-and-industry
Press release - 06/07/2012 Medicyte is receiving 4.2 Mio Euros from the European Union Seventh Framework Programm Medicyte, The Electrospinning Company and the Universities of Manchester and Pisa launch a European wide unique project with the aim to design a biomimetic bioartificial liver (Re-Liver). The company GABO:mi ensures professional project management. Research is receiving 4.2 Mio Euros from the European Union Seventh Framework Programme.https:////www.gesundheitsindustrie-bw.de/en/article/press-release/medicyte-is-receiving-4-2-mio-euros-from-the-european-union-seventh-framework-programm
Article - 25/06/2012 A special biobank for neurological research Over the last few years, the Hertie Institute for Clinical Brain Research in Tübingen has established a comprehensive biobank for use in neurological research. The databank is available to scientists from research institutions and companies working on research into neurological diseases such as Parkinson’s and Alzheimer’s with the aim of finding new options for the diagnostics and therapy of such diseases.https:////www.gesundheitsindustrie-bw.de/en/article/news/a-special-biobank-for-neurological-research-1
Article - 25/06/2012 CCCU biobank: indispensable for cancer researchers If everything goes according to plan, it takes no more than six minutes to prepare and place a tissue sample into the cryotank. Stored in liquid nitrogen at a temperature of minus 196°C, the biomaterial is ready to be used by the researchers from the Comprehensive Cancer Center at the Ulm University Hospital (CCCU). The biobank, which is currently being established at the CCCU, is funded by German Cancer Aid.https:////www.gesundheitsindustrie-bw.de/en/article/news/cccu-biobank-indispensable-for-cancer-researchers
Article - 18/06/2012 Not just a zoo for fish mutants The fish facilities of the Karlsruhe Institute of Technology KIT house around 9000 aquariums. Zebrafish with genetic defects are excellent model organisms for many biological studies. Prof. Dr. Uwe Strähle and his team at the Institute of Toxicology and Genetics ITG at KIT have been focusing for a long time on the development of the fish nervous system. The European Zebrafish Resource Center EZRC led by Prof. Strähle is currently being…https:////www.gesundheitsindustrie-bw.de/en/article/news/not-just-a-zoo-for-fish-mutants
Dossier - 18/06/2012 Biobanks – treasure chests for biomedical research Biobanking is still a very specialist subject. The Research Committee at the German Bundestag, the Office of Technology Assessment at the German Bundestag and the German Ethics Council are all interested in this biomedical research tool, which is both necessary and meaningful. However, opinions with regard to the ethical, legal and technical approach to biobanks differ. Since March 2012 it has become absolutely clear that Germany will not pass a…https:////www.gesundheitsindustrie-bw.de/en/article/dossier/biobanks-treasure-chests-for-biomedical-research
Dossier - 12/03/2012 Regenerative medicine makes use of patients’ own resources Regenerative medicine offers new therapeutic options for many diseases in which organ function or structure are damaged or lost. The majority of regenerative therapies involve cell-based methods that are often combined with innovative biomaterials. Regenerative therapies combine know-how from the biosciences with state-of-the-art medical technology and also benefit from progress in the engineering and material sciences.https:////www.gesundheitsindustrie-bw.de/en/article/dossier/regenerative-medicine-makes-use-of-patients-own-resources